Diabetic foot ulcers are usual and severe complication of diabetes mellitus, affecting tens of millions of human beings globally. They are persistent wounds that Increase at the feet of people with diabetes, mainly the ones who've suffer from high blood sugar or underlying diabetic neuropathy (nerve damage) and peripheral arterial sickness. Moreover, the development of a diabetic foot ulcer is frequently multifactorial, related to a combination of factors together with peripheral neuropathy, trauma, pressure and poor wound healing competencies. In addition, high blood sugar levels in diabetes can lead to nerve damage, reducing sensation in the feet, making it difficult for individuals to detect injuries or wounds. Further, poor circulation compromises the delivery of oxygen and nutrients to the feet, impairing wound healing. Furthermore, if left untreated or poorly managed, diabetic foot ulcers can lead to severe complications, Including infection, tissue necrosis (death) and in some cases, amputation. The management of diabetic foot ulcers requires a comprehensive approach that Includes wound care dressings & devices, off-loading techniques, infection control and addressing underlying factors contributing to the ulcer's development.
The major factors driving the development of the diabetic foot ulcer treatments are Increasing number of individuals suffering from diabetic foot ulcers, rise in R & D exercises, and surge in awareness about proper diabetic foot care. The predominance of diabetes is on the rise across the globe, fueled through factors which Include sedentary life, unhealthy diets, and growing obesity. Further, delayed periods of high blood sugar level can result in peripheral neuropathy, a condition that harms the nerves in the toes and diminishes sensation. In addition, poor blood circulation, known as peripheral arterial disease, advance impairs wound healing within the feet. These components, combined with the developing diabetic populace, contribute to an expanded frequency of diabetic foot ulcers. For instance, as per, Centers for Disease Control and Prevention (CDC), 2022, almost 12% individuals with diabetes develop diabetic foot ulcers in U.S. Thus, Increasing number of individuals suffering from diabetic foot ulcer has driven the request for compelling treatment options and thereby, propelling the development of the diabetic foot ulcer treatment market.
In addition, researchers and medical experts are actively involved in studying the pathophysiology of diabetic foot ulcers, exploring new treatment modalities and improving existing healing procedures. The use of advanced technology has caused the improvement of modern wound care products, bioengineered pores and skin substitutes and off-loading devices. These improvements aim to enhance wound healing, protect infections, and offer better management options for diabetic foot ulcers. Further, there are ongoing studies in field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing. The growing funding in research and development activities by pharmaceutical organizations, instructional institutions and healthcare companies has expanded the invention of novel therapeutic strategies, fueling the growth of the market.
Furthermore, surge in awareness about proper diabetic foot care has contributed to the growth of the diabetic foot ulcer treatment market. Healthcare organizations, diabetes associations, and healthcare professionals had been actively raising focus about the importance of foot care in individuals with diabetes. Diabetic foot ulcers can be averted or minimized through regular foot examinations, right shoes, foot hygiene, and early detection of foot ulcers. Furthermore, education campaigns and initiatives aimed at improving foot care practices have led to Increased patient awareness and engagement. As individuals become more aware about the risks and consequences of diabetic foot ulcers, they are more anticipated to seek timely medical attention and adhere to preventive measures. This heightened awareness has not only improved patient outcomes but has also driven the demand for diabetic foot ulcer treatment options.
The global diabetic foot ulcer treatment market is segmented into product, type, end user, and region. On the basis of product, the market is categorized into wound care dressings, wound care devices, biologics and others. The wound care devices segment is further categorized into negative pressure wound therapy and others. Based on type, it is categorized into neuropathic ulcers, ischemic ulcers and neuroischemic ulcers. As per end user, it is segregated into hospitals, homecare settings, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global diabetic foot ulcer treatment market are ConvaTec Group plc, 3M Company, Cardinal Health Inc., Organogenesis Holdings Inc., Smith and Nephew plc., B. Braun SE, Coloplast, Integra LifeSciences Holdings Corporation, Molnlycke Health Care AB, and Essity Aktiebolag AB. The key players have adopted strategies such as acquisition, contract, product launch, and product approval to expand their product portfolio.
The major factors driving the development of the diabetic foot ulcer treatments are Increasing number of individuals suffering from diabetic foot ulcers, rise in R & D exercises, and surge in awareness about proper diabetic foot care. The predominance of diabetes is on the rise across the globe, fueled through factors which Include sedentary life, unhealthy diets, and growing obesity. Further, delayed periods of high blood sugar level can result in peripheral neuropathy, a condition that harms the nerves in the toes and diminishes sensation. In addition, poor blood circulation, known as peripheral arterial disease, advance impairs wound healing within the feet. These components, combined with the developing diabetic populace, contribute to an expanded frequency of diabetic foot ulcers. For instance, as per, Centers for Disease Control and Prevention (CDC), 2022, almost 12% individuals with diabetes develop diabetic foot ulcers in U.S. Thus, Increasing number of individuals suffering from diabetic foot ulcer has driven the request for compelling treatment options and thereby, propelling the development of the diabetic foot ulcer treatment market.
In addition, researchers and medical experts are actively involved in studying the pathophysiology of diabetic foot ulcers, exploring new treatment modalities and improving existing healing procedures. The use of advanced technology has caused the improvement of modern wound care products, bioengineered pores and skin substitutes and off-loading devices. These improvements aim to enhance wound healing, protect infections, and offer better management options for diabetic foot ulcers. Further, there are ongoing studies in field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing. The growing funding in research and development activities by pharmaceutical organizations, instructional institutions and healthcare companies has expanded the invention of novel therapeutic strategies, fueling the growth of the market.
Furthermore, surge in awareness about proper diabetic foot care has contributed to the growth of the diabetic foot ulcer treatment market. Healthcare organizations, diabetes associations, and healthcare professionals had been actively raising focus about the importance of foot care in individuals with diabetes. Diabetic foot ulcers can be averted or minimized through regular foot examinations, right shoes, foot hygiene, and early detection of foot ulcers. Furthermore, education campaigns and initiatives aimed at improving foot care practices have led to Increased patient awareness and engagement. As individuals become more aware about the risks and consequences of diabetic foot ulcers, they are more anticipated to seek timely medical attention and adhere to preventive measures. This heightened awareness has not only improved patient outcomes but has also driven the demand for diabetic foot ulcer treatment options.
The global diabetic foot ulcer treatment market is segmented into product, type, end user, and region. On the basis of product, the market is categorized into wound care dressings, wound care devices, biologics and others. The wound care devices segment is further categorized into negative pressure wound therapy and others. Based on type, it is categorized into neuropathic ulcers, ischemic ulcers and neuroischemic ulcers. As per end user, it is segregated into hospitals, homecare settings, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global diabetic foot ulcer treatment market are ConvaTec Group plc, 3M Company, Cardinal Health Inc., Organogenesis Holdings Inc., Smith and Nephew plc., B. Braun SE, Coloplast, Integra LifeSciences Holdings Corporation, Molnlycke Health Care AB, and Essity Aktiebolag AB. The key players have adopted strategies such as acquisition, contract, product launch, and product approval to expand their product portfolio.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic foot ulcer treatment market analysis from 2022 to 2032 to identify the prevailing diabetic foot ulcer treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the diabetic foot ulcer treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global diabetic foot ulcer treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Wound care dressings
- Wound care devices
- Type
- Negative pressure wound therapy
- Others
- Biologics
- Others
By Type
- Neuropathic ulcers
- Ischemic ulcers
- Neuroischemic ulcers
By End user
- Hospitals
- Homecare settings
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- 3M Company
- B. Braun SE
- Cardinal Health Inc.
- Coloplast
- ConvaTec Group plc
- Essity Aktiebolag AB
- Integra LifeSciences Holdings Corporation
- Molnlycke Health Care AB
- ORGANOGENESIS HOLDINGS Inc.
- Smith and Nephew plc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT
CHAPTER 5: DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE
CHAPTER 6: DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER
CHAPTER 7: DIABETIC FOOT ULCER TREATMENT MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'Diabetic Foot Ulcer Treatment Market,' The diabetic foot ulcer treatment market was valued at $4.4 billion in 2022, and is estimated to reach $7.4 billion by 2032, growing at a CAGR of 5.4% from 2023 to 2032. Diabetic foot ulcers are a common and serious complication of diabetes mellitus. They are open sores or wounds that typically develop on the feet of individuals with diabetes. Diabetic foot ulcers are a result of various factors, including poor circulation, nerve damage (neuropathy), and impaired immune function, which are all associated with diabetes. If left untreated, diabetic foot ulcer can become chronic, leading to severe complications such as infection, gangrene, and even amputation. Thus, proper management and treatment of diabetic foot ulcers are crucial to prevent these complications and promote wound healing.Key factors driving the growth of the diabetic foot ulcer treatment market are rising prevalence of diabetes, advancements in wound care technology, increase in public awareness about diabetic foot care and rising healthcare infrastructure. The increasing prevalence of diabetes worldwide is a major driver for the diabetic foot ulcer treatment market. Diabetes is a chronic condition that affects the body's ability to regulate blood sugar levels, leading to various complications, including foot ulcers. As the number of diabetic patients continues to rise, the demand for effective treatment options for diabetic foot ulcers also increases. Further, diabetic foot ulcer treatment market has witnessed significant technological advancements in recent years. Innovations such as advanced wound care products, bioengineered skin substitutes, growth factors, negative pressure wound therapy and hyperbaric oxygen therapy have improved the healing outcomes for diabetic foot ulcers. These advancements attract healthcare providers and patients, leading to increased adoption and driving market growth.
In addition, development of advanced wound dressings has revolutionized diabetic foot ulcer treatment. These dressings are designed to create an optimal wound healing environment by maintaining moisture balance, providing a barrier against bacteria, promoting angiogenesis and facilitating the removal of necrotic tissue. Examples include foam dressings, hydrocolloids, hydrogels, alginate dressings, and silver-based dressings. Further, bioactive materials such as growth factors, extracellular matrices, and tissue-engineered products are being adopted in wound healing and tissue regeneration. These materials can stimulate cellular activities, promote angiogenesis and enhance the formation of new tissue. They are often used as adjunctive therapies to accelerate the healing of diabetic foot ulcers.
Furthermore, there has been a significant increase in public awareness and education regarding diabetes and its complications, including diabetic foot ulcers. Governments, healthcare organizations, and non-profit entities are actively involved in promoting awareness campaigns, educating individuals about diabetes management, and encouraging early intervention for foot ulcers. This heightened awareness drives the demand for effective treatment options and stimulates the market growth. Moreover, collaboration between pharmaceutical companies, medical device manufacturers, research institutions and healthcare providers play a significant role in advancing diabetic foot ulcer treatments. These collaborations foster research and development efforts, leading to the introduction of new and improved wound care products in the market. Partnerships also aid in increasing product reach, expanding market presence and drive the market growth. The market also offers growth opportunities to the key players in the market. Many developing regions such India and Brazil offer lucrative opportunities to key players of diabetic foot ulcer treatment market owing to increase in demand of novel treatment options for diabetic foot ulcer, increase in diabetes cases and rise healthcare spending.
The global diabetic foot ulcer treatment market is segmented into product, type, end user, and region. On the basis of product, the market is categorized into wound care dressings, wound care devices, biologics and others. The wound care devices segment is further categorized into negative pressure wound therapy and others. Based on type, it is categorized into neuropathic ulcers, ischemic ulcers and neuroischemic ulcers. As per end user, it is segregated into hospitals, homecare settings, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). The key players profiled in the study include ConvaTec Group plc, 3M Company, Cardinal Health Inc., Organogenesis Holdings Inc., Smith and Nephew plc., B. Braun SE, Coloplast, Integra LifeSciences Holdings Corporation, Molnlycke Health Care AB, and Essity Aktiebolag AB. The key players have adopted strategies such as acquisition, contract, product launch and product approval to expand their product portfolio.
Key Market Insights
- On the basis of product, the wound care dressings segment dominated the market in terms of revenue in 2022. However, the wound care devices segment is expected to grow at the highest CAGR during the forecast period.
- Based on type, the neuroischemic ulcers segment accounted for largest share in terms of revenue in 2022 and is anticipated to witness highest CAGR during the forecast period.
- On the basis of end user, the homecare settings segment dominated the market in terms of revenue in 2022, and is anticipated to grow at the highest CAGR during the forecast period.
- Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- 3M Company
- B. Braun SE
- Cardinal Health Inc.
- Coloplast
- ConvaTec Group plc
- Essity Aktiebolag AB
- Integra LifeSciences Holdings Corporation
- Molnlycke Health Care AB
- ORGANOGENESIS HOLDINGS INC.
- Smith and Nephew plc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
